Loading...
XSTO
LIPUM
Market cap33mUSD
Jun 11, Last price  
14.95SEK
1D
0.00%
1Q
1.01%
IPO
-40.20%
Name

Lipum AB (publ)

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
35.20%
Rev. gr., 5y
-20.63%
Revenues
0k
-100.00%
0039,06014,8030053,0000
Net income
-56m
L+49.32%
00-9,316,318-21,137,413-52,406,000-38,245,000-37,178,000-55,516,000
CFO
-87m
L+139.53%
000-19,370,000-34,296,000-52,406,000-36,126,000-86,534,000

Profile

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
IPO date
Apr 22, 2021
Employees
5
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
53
 
Cost of revenue
26,001
61,432
Unusual Expense (Income)
NOPBT
(25,948)
(61,432)
NOPBT Margin
Operating Taxes
160
Tax Rate
NOPAT
(25,948)
(61,592)
Net income
(55,516)
49.32%
(37,178)
-2.79%
(38,245)
-27.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
79,715
15,276
39,161
BB yield
-31.04%
-28.07%
-44.19%
Debt
Debt current
10,000
Long-term debt
1,868
1,761
1,661
Deferred revenue
Other long-term liabilities
(1,661)
Net debt
5,236
(8,465)
(31,176)
Cash flow
Cash from operating activities
(86,534)
(36,126)
(52,406)
CAPEX
(188)
(60)
Cash from investing activities
(188)
(60)
Cash from financing activities
82,915
13,703
38,250
FCF
(27,104)
(26,096)
(61,641)
Balance
Cash
6,632
10,226
32,837
Long term investments
Excess cash
6,632
10,223
32,837
Stockholders' equity
(213,743)
(161,201)
(124,438)
Invested Capital
247,607
167,534
153,650
ROIC
ROCE
EV
Common stock shares outstanding
21,400
8,346
6,353
Price
12.00
84.05%
6.52
-53.26%
13.95
-24.59%
Market cap
256,795
371.91%
54,416
-38.60%
88,629
15.32%
EV
262,031
45,951
57,453
EBITDA
(25,908)
(61,421)
EV/EBITDA
Interest
534
169
Interest/NOPBT